The existing evidence supporting its use is weak and often compromised by conflicts of interest
Key resources include: ClinicalTrials.gov Search for new trials involving cagrilintide or retatrutide PubMed/MEDLINE Set alerts for publications on these compounds Major medical journals New England Journal of Medicine, The Lancet, JAMA for high-impact studies Endocrine Society conferences Annual meetings where phase 3 data is often first presented FDA briefing documents Detailed safety and efficacy data released during approval processes Understanding the broader landscape of peptide research helps contextualize developments with specific compounds
Bjorbaek C, Elmquist JK, Michl P, Ahima RS, van Bueren A, McCall AL, et al
Inject the BAC water very slowly , letting it run down the side of the vial
The product must be reconstituted with bacteriostatic water using sterile technique to ensure safety and efficacy
the plasma level of the compound reaches its peak within 1 hour after intramuscular injection